
MARAVAI LIFESCIENCES HLDGS-A
MRVINASDAQTrading Snapshot
- Day Range
- $600.59 β $615.11
- 52-Week Range
- $2.03 β $7.44
- Volume
- $2.51B
- Avg Volume
- $2.37B
- Shares Outstanding
- 258.2M
- Next Earnings
- Sep 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $186M
- Last Q Revenue
- $51M
- P/E Ratio
- β
- P/S Ratio
- 7.5x
- EPS (TTM)
- $-0.53
- Dividend Yield
- β
Why Investors Own MRVI
- βHigh-growth profile β revenue up +56.0% YoY with expanding US Equity exposure.
- βHealthy economics β 58% gross margin and 25% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MARAVAI LIFESCIENCES HLDGS-A
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
MARAVAI LIFESCIENCES HLDGS-A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift MRVI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
MARAVAI LIFESCIENCES HLDGS-A announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.